Onyx Pharmaceuticals Inc Sample Contracts

RECITALS
Onyx Pharmaceuticals Inc • March 27th, 2000 • Biological products, (no disgnostic substances)
Sample 1Sample 2Sample 3See All (998)
AutoNDA by SimpleDocs
Exhibit 1.1 ----------- JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.001 per share, of Onyx...
Joint Filing Agreement • February 14th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)

The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.001 per share, of Onyx Pharmaceuticals Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

Sample 1Sample 2Sample 3See All (997)
Exhibit 1.1 5,000,000 SHARES ONYX PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT July 21, 2003 Morgan Stanley & Co. Incorporated Lehman Brothers Inc. SG Cowen Securities Corporation c/o Morgan Stanley & Co....
Onyx Pharmaceuticals Inc • July 22nd, 2003 • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (777)
Exhibit 1.1 3,000,000 SHARES (1) ONYX PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT
Onyx Pharmaceuticals Inc • October 11th, 2000 • Biological products, (no disgnostic substances) • Minnesota
Sample 1Sample 2Sample 3See All (627)
ONYX PHARMACEUTICALS, INC., ISSUER AND WELLS FARGO BANK, N.A., TRUSTEE INDENTURE
Onyx Pharmaceuticals Inc • January 20th, 2005 • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (340)
ONYX PHARMACEUTICALS, INC. AND , AS WARRANT AGENT COMMON STOCK WARRANT AGREEMENT DATED AS OF
Common Stock Warrant Agreement • January 15th, 2013 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ONYX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (266)
ONYX PHARMACEUTICALS, INC. ISSUER AND WELLS FARGO BANK, N.A. TRUSTEE INDENTURE
Onyx Pharmaceuticals Inc • January 20th, 2005 • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (235)
ONYX PHARMACEUTICALS, INC. AND , AS WARRANT AGENT PREFERRED STOCK WARRANT AGREEMENT DATED AS OF
Preferred Stock Warrant Agreement • January 15th, 2013 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ONYX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (199)
AND
Warrant Agreement • January 20th, 2005 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (185)
Underwriting Agreement
Underwriting Agreement • January 17th, 2013 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (163)
EXHIBIT 10.28 ONYX PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT
Stock Purchase Agreement • March 1st, 2000 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (130)
March 10, 1997 IMPERIAL BANK Member FDIC Borrower: ONYX Pharmaceuticals, Inc. 226 Airport Parkway San Jose, California Subject: Credit Terms and Conditions ("Agreement") Gentlemen: To induce you to make loans to the undersigned (herein called...
General Security Agreement • March 31st, 1997 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
Sample 1Sample 2Sample 3See All (123)
ONYX PHARMACEUTICALS, INC. AND , AS WARRANT AGENT DEBT SECURITIES WARRANT AGREEMENT DATED AS OF
Debt Securities Warrant Agreement • January 15th, 2013 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ONYX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (113)
AGREEMENT
Stock and Warrant Purchase Agreement • May 30th, 2002 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (89)
EXHIBIT 99.1 PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENT
Certain • February 23rd, 2001 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
Sample 1Sample 2Sample 3See All (34)
ONYX PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT JANUARY 12, 1998
Stock Purchase Agreement • January 26th, 1998 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
Sample 1Sample 2Sample 3See All (12)
ONYX PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ONYX PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT
Debt Securities Warrant Agreement • May 30th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

Debt Securities Warrant Agreement, dated as of ___, between Onyx Pharmaceuticals, Inc., a Delaware corporation (the “COMPANY”) and ___, a [corporation] [national banking association] organized and existing under the laws of ___ and having a corporate trust office in ___, as warrant agent (the “WARRANT AGENT”).

Sample 1Sample 2Sample 3See All (6)
AGREEMENT AND PLAN OF MERGER by and among: ONYX PHARMACEUTICALS, INC., a Delaware corporation; AMGEN INC., a Delaware corporation; and ARENA ACQUISITION COMPANY, a Delaware corporation Dated as of August 24, 2013
Agreement and Plan of Merger • August 26th, 2013 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (6)
ONYX PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ONYX PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT
Common Stock Warrant Agreement • May 30th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

Common Stock Warrant Agreement, dated as of , between Onyx Pharmaceuticals, Inc., a Delaware corporation (the “COMPANY”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “WARRANT AGENT”).

Sample 1Sample 2Sample 3See All (5)
Onyx Pharmaceuticals, Inc. 4,000,000 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • August 7th, 2009 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

The undersigned understands that you, as representative (the “Representative”), propose to enter into (i) an Underwriting Agreement (the “Common Stock Underwriting Agreement”) on behalf of the several underwriters named in Schedule I to such agreement (the “Common Stock Underwriters”), with Onyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), providing for the offer and sale of the common stock of the Company, $0.001 par value per share (the “Stock”) and (ii) an Underwriting Agreement (the “Convertible Notes Underwriting Agreement”) on behalf of the several underwriters named in Schedule I to such agreement (the “Convertible Notes Underwriters”), with the Company, providing for the offer and sale of the Company’s Convertible Senior Notes due 2016 (the “Notes” and, together with the Stock, the “Securities”). The Notes will be convertible into shares of Stock.

Sample 1Sample 2Sample 3See All (5)
ONYX PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ONYX PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT
Preferred Stock Warrant Agreement • May 30th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

PREFERRED STOCK WARRANT AGREEMENT, dated as of between ONYX PHARMACEUTICALS, INC., a Delaware corporation (the “COMPANY”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “WARRANT AGENT”).

Sample 1Sample 2Sample 3See All (5)
AND
Onyx Pharmaceuticals Inc • January 20th, 2005 • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
5,000,000 Shares ONYX PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT
Underwriting Agreement • November 18th, 2005 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

Onyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) 5,000,000 shares of its common stock, par value $0.001 per share (the “Firm Shares”). The Company also proposes to issue and sell to the several Underwriters not more than an additional 750,000 shares of its common stock, par value $0.001 per share (the “Additional Shares”), if and to the extent that you, as representatives of the Underwriters for the offering, shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares of common stock, par value $0.001 per share, of the Company are hereinafter referred to as the “Common Stock.”

Sample 1Sample 2Sample 3
W I T N E S S E T H
Onyx Pharmaceuticals Inc • March 31st, 1998 • Biological products, (no disgnostic substances)
Sample 1Sample 2Sample 3
COMMON STOCK PURCHASE AGREEMENT Dated September 29, 2006 by and between ONYX PHARMACEUTICALS, INC. and AZIMUTH OPPORTUNITY LTD.
Common Stock Purchase Agreement • September 29th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware

This COMMON STOCK PURCHASE AGREEMENT, made and entered into on this 29th day of September 2006 (this “Agreement”), by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), and Onyx Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”).

Sample 1Sample 2Sample 3
Contract
Collaboration Agreement • May 10th, 2011 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED.

Sample 1Sample 2
Onyx Pharmaceuticals, Inc. 4.00% Convertible Senior Notes Due 2016 Underwriting Agreement
Underwriting Agreement • August 7th, 2009 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

The undersigned understands that you, as representative (the “Representative”), propose to enter into (i) an Underwriting Agreement (the “Common Stock Underwriting Agreement”) on behalf of the several underwriters named in Schedule I to such agreement (the “Common Stock Underwriters”), with Onyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), providing for the offer and sale of the common stock of the Company, $0.001 par value per share (the “Stock”) and (ii) an Underwriting Agreement (the “Convertible Notes Underwriting Agreement”) on behalf of the several underwriters named in Schedule I to such agreement (the “Convertible Notes Underwriters”), with the Company, providing for the offer and sale of the Company’s Convertible Senior Notes due 2016 (the “Notes” and, together with the Stock, the “Securities”). The Notes will be convertible into shares of Stock.

Sample 1Sample 2
STOCK TRANSFER AGREEMENT THIS STOCK TRANSFER AGREEMENT is entered into as of January 12, 1998, by and between LOMBARD ODIER & CIE (the "PURCHASER"), CHIRON CORPORATION ("CHIRON") and, in regards to Section 3 only, ONYX PHARMACEUTICALS, INC. (the...
Stock Transfer Agreement • April 2nd, 1998 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
Sample 1Sample 2
AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENT
Control Severance Benefits Agreement • May 18th, 2011 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California

This Amended and Restated Executive Change in Control Severance Benefits Agreement (the “Agreement”) is entered into as of May 18, 2011 (the “Effective Date”), between Kaye Foster-Cheek (“Executive”) and Onyx Pharmaceuticals, Inc. (the “Company”) and amends and restates the prior Executive Change in Control Severance Benefits Agreement between the Company and Executive dated September 30, 2010 (the “Original Date”). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to a qualifying termination of employment in connection with a Change in Control. Certain capitalized terms used in this Agreement are defined in Article 5.

Sample 1Sample 2
AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT
Development and Marketing Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Sample 1Sample 2
EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENT This form of Executive Change in Control Severance Benefits Agreement may be entered into between Onyx Pharmaceuticals, Inc. and each of its Executive Vice Presidents (“EVP”), Senior Vice...
Executive Change in Control Severance Benefits Agreement • June 10th, 2008 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California

This Executive Change in Control Severance Benefits Agreement (the “Agreement”) is entered into as of the ___ day of , 20___ (the “Effective Date”), between (“Executive”) and Onyx Pharmaceuticals, Inc. (the “Company”). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment in connection with a Change in Control. Certain capitalized terms used in this Agreement are defined in Article 5.

Sample 1Sample 2
September 6, 2006 Fabio Benedetti, M.D. Onyx Pharmaceuticals, Inc. 2100 Powell Street Emeryville, CA 94608 Dear Fabio:
Onyx Pharmaceuticals Inc • September 7th, 2006 • Biological products, (no disgnostic substances) • California

This letter sets forth the terms of our agreement with respect to the termination of your employment with Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”).

Sample 1Sample 2
BETWEEN
Collaboration Agreement • March 1st, 2000 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2
AND
Onyx Pharmaceuticals Inc • January 20th, 2005 • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2
SECOND AMENDMENT TO THE RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC., A DELAWARE CORPORATION (“ONYX”), and WARNER-LAMBERT COMPANY, A DELAWARE CORPORATION (“WARNER”).
Development and Marketing Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)

THIS SECOND AMENDMENT (“Second Amendment”) to the RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT (“Agreement”), having an effective date of July 31, 1997, between Onyx and Warner, which Agreement was first amended on August 2, 1999 to extend its term one year, is entered into and made effective March 1, 2000. Onyx and Warner may be referred to herein individually as “Party,” or collectively, as the “Parties.”

Sample 1
Time is Money Join Law Insider Premium to draft better contracts faster.